# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

#### **SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Filed	l by the	Registrant ⊠	Filed by a Party other than the Registrant $\ \Box$					
Chec	ck the a	ppropriate box:						
	Prelir	Preliminary Proxy Statement						
	Conf	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))						
	Definitive Proxy Statement							
$\boxtimes$	Defin	itive Additional Materia	S					
	Solici	ting Material under Rul	rial under Rule 14a-12					
		2	KERIS PHARMACEUTICALS, INC. (Name of Registrant as Specified in Its Charter)					
Payr	nent of	Filing Fee (Check the a	propriate box):					
$\boxtimes$	No fe	o fee required.						
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.							
	(1)	Title of each class of se	curities to which transaction applies:					
	(2)	Aggregate number of so	curities to which transaction applies:					
	(3)		nderlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the how it was determined):	the filing				
	(4)	Proposed maximum ag	regate value of transaction:					
	(5)	Total fee paid:						
	Fee p	aid previously with prel	minary materials.					
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.							
	(1)	Amount Previously Pai	l:					
	(2)	Form, Schedule or Reg	stration Statement No.:					
	(3)	Filing Party:						

(4)	Date Filed:					



## Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be held on May 8, 2019, for Xeris Pharmaceuticals, Inc.

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement and annual report, go to <a href="https://www.proxydocs.com/XERS">www.proxydocs.com/XERS</a>. To submit your proxy while visiting this site, you will need the 12 digit control number in the box below.

- 0	
	Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. We have chosen to use these procedures for our 2019 Annual Meeting and need YOUR participation.
	If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's annual meeting, please make this request on or before April 26, 2019.



### For a Convenient Way to VIEW Proxy Materials

– and –

### **VOTE Online go to: www.proxydocs.com/XERS**

Proxy Materials Available to View or Receive: 1. Proxy Statement 2. Annual Report

Printed materials may be requested by one of the following methods:




www.investorelections.com/XERS



**TELEPHONE** (866) 648-8133



If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material.



ACCOUNT NO.

SHARES



Xeris

Date: Wednesday, May 8, 2019

Time: 08:00 A.M. (Central Daylight Time)

**Company Notice of Annual Meeting** 

Place: 180 N. LaSalle Street, Suite 1600, Chicago, IL 60601

The purpose of the Annual Meeting is to take action on the following proposals:

The Board of Directors recommends that you vote "FOR" each of the nominees listed below.

Election of Directors
 Ol John Schmid

02 BJ Bormann, Ph.D.

The Board of Directors recommends that you vote "FOR" the following.

2. Ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2019.

NOTE: To transact any other business properly brought before the Annual Meeting (including adjournments or postponments thereof)